Dr. Reggie Ewesuedo, VP of Clinical Development at Lantern Pharma, discusses how AI-driven drug discovery has unlocked LP-300, a promising new therapy. In this exclusive interview, he highlights the positive Phase 2 HARMONIC™ trial results for never-smokers with lung cancer, which a patient group long underserved by traditional treatments.
